© 2006 European Society for Medical Oncology
symposium article |
Apoptosis: a relevant tool for anticancer therapy
1 Section of Medical Oncology, Department of Surgical and Oncology, Università di Palermo; 2 Medical Oncology, University Campus Bio-Medico, Rome, Italy
* Correspondence to: Dr A. Russo, Section of Medical Oncology, Department of Oncology, Università di Palermo, Via del Vespro 127, 90127 Palermo, Italy. Tel: +39-091-6552500; Fax: +39-091-6554529; E-mail: lab-oncobiologia{at}usa.net
Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the extrinsic/intrinsic pathway, proteins that control the apoptosis machinery such as the p53 and proteosome pathway. Most of these forms of therapy are still in preclinical development because of their low specifity and susceptibility to drug resistance, but several of them have shown promising results. In particular, this review specifically aims at providing an update of certain molecular players that are already in use in order to target apoptosis (such as bortezomib) or which are still being clinically evaluated (such ONYX-015, survivin and exisulind/aptosyn) or which, following preclinical studies, might have the necessary requirements for becoming part of the anticancer drug programs (such as TRAIL/Apo2L, apoptin/VP3).
Key words: apoptosis, TRAIL/Apo2L, apoptin/VP3, ONYX015, Bortezomib, exisulind, survivin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-I. Liu, C.-C. Huang, C.-J. Huang, B.-W. Wang, P.-M. Chang, Y.-C. Fang, W.-C. Chen, J.-L. Wang, Y.-C. Lu, S.-T. Chu, et al. Thimerosal-Induced Apoptosis in Human SCM1 Gastric Cancer Cells: Activation of p38 MAP Kinase and Caspase-3 Pathways without Involvement of [Ca2+]i Elevation Toxicol. Sci., November 1, 2007; 100(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al. Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis Clin. Cancer Res., June 1, 2007; 13(11): 3403 - 3412. [Abstract] [Full Text] [PDF]
|
|